{
    "2019-09-01": [
        [
            {
                "time": "",
                "original_text": "复星医药董事长陈启宇：抗癌创新药降价是必经之路",
                "features": {
                    "keywords": [
                        "复星医药",
                        "抗癌创新药",
                        "降价",
                        "必经之路"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-09-09",
                "original_text": "【民生医药|周报】09/09：政策影响钝化，二线公司关注度提升",
                "features": {
                    "keywords": [
                        "民生医药",
                        "周报",
                        "政策影响",
                        "钝化",
                        "二线公司",
                        "关注度提升"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}